Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cck-8
2. Cck-op
3. Cholecystokinin Octapeptide
4. Cholecystokinin Pancreozymin C Terminal Octapeptide
5. Cholecystokinin Pancreozymin C-terminal Octapeptide
6. H-asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2
7. Kinevac
8. Op-cck
9. Sq 19,844
10. Sq 19844
11. Sq-19,844
12. Sq-19844
13. Sq19,844
14. Sq19844
15. Syncalide
1. 25126-32-3
2. Cck-8
3. Kinevac
4. Sq 19844
5. Cck C-terminal Octapeptide
6. Cholecystokinin C-terminal Octapeptide
7. Sq-19844
8. Chembl1121
9. M03giq7z6p
10. Cholecystokinin Octapeptide
11. Caerulein, 1-de(5-oxo-l-proline)-2-de-l-glutamine-5-l-methionine-
12. H-asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2
13. Cholecystokinin 8
14. Dsstox_cid_28543
15. Dsstox_rid_82815
16. Dsstox_gsid_48617
17. L-aspartyl-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-aspartylphenyl-l-alaninamide Hydrogen Sulfate (ester)
18. Sincalidum
19. Sincalida
20. Syncalide
21. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-(((s)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosanedioic Acid
22. Cas-25126-32-3
23. Human Cck-8
24. Cck-8 (sulphated)
25. Asp-tyr(so3h)-met-gly-trp-met-asp-phe-nh2
26. Sincalidum [inn-latin]
27. Sincalida [inn-spanish]
28. Unii-m03giq7z6p
29. Pancreozymin
30. Sincalide [usan:usp:inn:ban]
31. Ncgc00183278-01
32. Ncgc00183363-01
33. 3-10-caerulein, 5-l-methionine-
34. Einecs 246-639-0
35. Kinevac (tn)
36. Mfcd00079849
37. Sq19844
38. Sincalide [inn]
39. Sincalide [mi]
40. Sincalide (usan/inn)
41. Sincalide [usan]
42. Sincalide [vandf]
43. Cholecystokinin-pancreozymin
44. Sincalide [mart.]
45. Sincalide [who-dd]
46. Cholecystokinin Fragment 26-33 Amide (sulphated)
47. Gtpl864
48. Schembl122365
49. (tyr[so3h]27)cholecystokinin Fragment 26-33 Amide
50. Cck-8(so3)
51. Sincalide [orange Book]
52. Dtxsid7048617
53. Sincalide [usp Impurity]
54. Bdbm21147
55. Chebi:135946
56. (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-(4-sulfooxyphenyl)propan-2-yl]amino]-4-oxobutanoic Acid
57. [125i]cck-8
58. 1-de(5-oxo-l-proline)-2-de-l-glutamine-5-l-methioninecaerulein
59. Hy-p0093
60. Sq19844cholecystokinin Octapeptide
61. Tox21_112955
62. Tox21_113481
63. Cholecystokinin Octapeptide, Sulfated
64. Coralynechloridehydrate,98+%
65. Akos016340423
66. Cs-5963
67. Db09142
68. Hs-2026
69. Ncgc00167273-01
70. L-alpha-aspartyl-o-sulfo-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-alpha-aspartyl-l-phenylalaninamide
71. Cholecystokinin, Cck Octapeptide (26-33)
72. D05845
73. E78048
74. Asp26-tyr(so3h)-met-gly-trp-met-asp-phenh2
75. 126s323
76. Cholecystokinin C-terminal Octapeptide [mi]
77. Cholecystokinin Octapeptide (sulfated) Ammonium Salt
78. Q7521885
79. (3s)-3-[(2s)-2-[(2s)-2-{2-[(2s)-2-[(2s)-2-[(3s)-3-amino-3-formamidopropanoic Acid]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1h-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1s)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic Acid
80. (3s)-3-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-hydroxy-4-oxobutanoyl]amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic Acid
81. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-(((s)-1-amino-1-oxo-3-phenylpropan-2-yl)carbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic Acid
82. (3s,6s,9s,15s,18s,21s)-9-((1h-indol-3-yl)methyl)-21-amino-3-((s)-1-amino-1-oxo-3-phenylpropan-2-ylcarbamoyl)-6,15-bis(2-(methylthio)ethyl)-5,8,11,14,17,20-hexaoxo-18-(4-(sulfooxy)benzyl)-4,7,10,13,16,19-hexaazatricosane-1,23-dioic Acid
83. L-.alpha.-aspartyl-o-sulfo-l-tyrosyl-l-methionylglycyl-l-tryptophyl-l-methionyl-l-.alpha.-aspartyl-l-phenylalaninamide
Molecular Weight | 1143.3 g/mol |
---|---|
Molecular Formula | C49H62N10O16S3 |
XLogP3 | -2.6 |
Hydrogen Bond Donor Count | 13 |
Hydrogen Bond Acceptor Count | 19 |
Rotatable Bond Count | 33 |
Exact Mass | 1142.35073945 g/mol |
Monoisotopic Mass | 1142.35073945 g/mol |
Topological Polar Surface Area | 486 Ų |
Heavy Atom Count | 78 |
Formal Charge | 0 |
Complexity | 2180 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
As the product Kinevac (FDA), sincalide is used for the following indications: 1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.
FDA Label
V - Various
V04 - Diagnostic agents
V04C - Other diagnostic agents
V04CC - Tests for bile duct patency
V04CC03 - Sincalide
Absorption
The intravenous (bolus) administration of sincalide causes a prompt contraction of the gallbladder that becomes maximal in 5 to 15 minutes, as compared with the stimulus of a fatty meal which causes a progressive contraction that becomes maximal after approximately 40 minutes.
When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Like cholecystokinin, sincalide stimulates pancreatic secretion; concurrent administration with secretin increases both the volume of pancreatic secretion and the output of bicarbonate and protein (enzymes) by the gland. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function through measurement and analysis of the duodenal aspirate.
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?